US 12,264,359 B2
CRISPR enzymes and systems
Feng Zhang, Cambridge, MA (US); Bernd Zetsche, Cambridge, MA (US); Jonathan S. Gootenberg, Cambridge, MA (US); Omar O. Abudayyeh, Cambridge, MA (US); and Ian Slaymaker, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Jun. 23, 2020, as Appl. No. 16/909,101.
Application 16/909,101 is a continuation of application No. 16/048,038, filed on Jul. 27, 2018, granted, now 11,091,798.
Application 16/048,038 is a continuation of application No. 15/844,608, filed on Dec. 17, 2017, granted, now 10,648,020, issued on May 12, 2020.
Application 15/844,608 is a continuation in part of application No. PCT/US2016/038181, filed on Jun. 17, 2016.
Application PCT/US2016/038181 is a continuation in part of application No. 14/975,085, filed on Dec. 18, 2015, granted, now 9,790,490, issued on Oct. 17, 2017.
Claims priority of provisional application 62/232,067, filed on Sep. 24, 2015.
Claims priority of provisional application 62/205,733, filed on Aug. 16, 2015.
Claims priority of provisional application 62/201,542, filed on Aug. 5, 2015.
Claims priority of provisional application 62/193,507, filed on Jul. 16, 2015.
Claims priority of provisional application 62/181,739, filed on Jun. 18, 2015.
Claims priority of application No. 16150428 (EP), filed on Jan. 7, 2016.
Prior Publication US 2020/0318173 A1, Oct. 8, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6832 (2018.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12Q 1/6816 (2018.01)
CPC C12Q 1/6832 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12Q 1/6816 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 47 Claims
 
1. A method of altering expression of a gene in a mammalian cell, comprising delivering to the mammalian cell:
(a) a Cpf1 protein, or a polynucleotide encoding the Cpf1 protein, and
(b) a Cpf1 guide comprising a guide sequence capable of hybridizing with a target sequence associated with the gene, or a polynucleotide encoding the Cpf1 guide,
wherein a CRISPR complex formed by the Cpf1 guide and the Cpf1 protein binds to the target sequence and alters expression of the gene, thereby producing a modified mammalian cell.